CD26/DPP4-a potential biomarker and target for cancer therapy
N Enz, G Vliegen, I De Meester… - Pharmacology & …, 2019 - Elsevier
Abstract CD26/dipeptidyl peptidase (DPP) 4 is a membrane-bound protein found in many
cell types of the body, and a soluble form is present in body fluids. There is longstanding …
cell types of the body, and a soluble form is present in body fluids. There is longstanding …
The role of dipeptidyl peptidase‐4 in cutaneous disease
Abstract Dipeptidyl peptidase‐4 (DPP4) is a multifunctional, transmembrane glycoprotein
present on the cell surface of various tissues. It is present in multiple molecular forms …
present on the cell surface of various tissues. It is present in multiple molecular forms …
The serine protease CD26/DPP4 in non-transformed and malignant T Cells
Simple Summary The transmembrane serine protease CD26/Dipeptidylpeptidase 4
modulates T-cell activation, proliferation, and effector function. Due to their remarkable …
modulates T-cell activation, proliferation, and effector function. Due to their remarkable …
Spatially guided and single cell tools to map the microenvironment in cutaneous T-cell lymphoma
E Kalliara, E Belfrage, U Gullberg, K Drott, S Ek - Cancers, 2023 - mdpi.com
Simple Summary While most patients with cutaneous T-cell lymphoma (CTCL) may be
diagnosed with early-stage disease, approximately 25–30% of those patients will …
diagnosed with early-stage disease, approximately 25–30% of those patients will …
Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials
B Farabi, L Seminario‐Vidal… - Journal of cosmetic …, 2022 - Wiley Online Library
Background Ten‐year survival rates in mycosis fungoides (MF) broadly varies, however,
there is no standardized prognostic index available. This is presumably due to low …
there is no standardized prognostic index available. This is presumably due to low …
PEG10 amplification at 7q21. 3 potentiates large-cell transformation in cutaneous T-cell lymphoma
F Liu, Y Gao, B Xu, S **ong, S Yi, J Sun… - Blood, The Journal …, 2022 - ashpublications.org
Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma, undergo
large-cell transformation (LCT) in the late stage, manifesting aggressive behavior, resistance …
large-cell transformation (LCT) in the late stage, manifesting aggressive behavior, resistance …
Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas
As a major cancer hallmark, there is a sustained interest in understanding the telomerase
contribution to carcinogenesis in order to therapeutically target this enzyme. This is …
contribution to carcinogenesis in order to therapeutically target this enzyme. This is …
Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: a single-center retrospective study
M O'Donnell, R Zaya, E Correia, S Krishnasamy… - Journal of the American …, 2022 - Elsevier
Background Mycosis fungoides with large-cell transformation (MF-LCT) is associated with
an aggressive clinical course, yet data comparing treatment outcomes in MF-LCT are …
an aggressive clinical course, yet data comparing treatment outcomes in MF-LCT are …
Mycosis fungoides with spongiosis: A potential diagnostic pitfall
H Shamim, EF Johnson, LE Gibson… - Journal of Cutaneous …, 2019 - Wiley Online Library
Background Mycosis fungoides (MF) is characterized by epidermotropic atypical
lymphocytes in the absence of spongiosis. However, we describe an unusual presentation …
lymphocytes in the absence of spongiosis. However, we describe an unusual presentation …
[HTML][HTML] High expression of Ikzf2 in Malignant T cells promotes disease progression in cutaneous T cell lymphoma
XU Bufang, LIU Fengjie, GAO Yumei… - Acta dermato …, 2021 - ncbi.nlm.nih.gov
Cutaneous T cell lymphoma is a generally indolent disease derived from skin-homing
mature T cells. However, in advanced stages, cutaneous T cell lymphoma may manifest …
mature T cells. However, in advanced stages, cutaneous T cell lymphoma may manifest …